We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hutchmed (china) Limited | LSE:HCM | London | Ordinary Share | KYG4672N1198 | ORD USD0.10 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-6.50 | -2.14% | 297.50 | 296.00 | 299.00 | 309.00 | 298.00 | 306.00 | 123,751 | 16:35:10 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 838M | 100.78M | - | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
03/6/2023 09:21 | yes I think you are right - geo-politics and anti-chinese sentiment are playing a major role here but what surprises me is that the NASDAQ listing seems to control London and HK prices. I was expecting and hoping that inclusion in certain chinese indexes and the southbound stock connect program would mean a big influx of chinese investors and that would mean theat the HK listing would become dominant, but that hasn't happened. | nerdofsteel | |
02/6/2023 21:46 | The story and the performance havve not changed. Only the political background holds HCM back. I think the relationship with Takeda will go a long way to fix that. | dbadvn | |
31/5/2023 07:38 | I may do that, although I did it at 300p and that clearly didn't work - another failed investment strategy | nerdofsteel | |
30/5/2023 20:21 | Time to double down and load up. | its the oxman | |
30/5/2023 17:48 | 8 years of progress wiped out, now back below NASDAQ IPO levels of 2016 and below share price levels of mid 2015 The valuation is truly shocking and makes no sense at all any more | nerdofsteel | |
26/5/2023 01:48 | Should see a turn today: Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review Great to see the Takeda effect and hope more is to come. HCM also sent another news release at the same time: HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting | lauders | |
24/5/2023 17:00 | shorts, malaise, geo-politics, anti-china rhetoric, Taiwan etc etc..... | nerdofsteel | |
20/5/2023 16:26 | hmmmm not sure steeple but I'm probably | nerdofsteel | |
19/5/2023 19:51 | https://youtu.be/8LM | steeplejack | |
18/5/2023 19:22 | Biden Executive order to put restrictions on U.S. companies investing in chinese companies and having operations in China in sectors such as advanced semi-conductors, AI, electronics etc. Whilst the drug/biopharma sector is not mentioned specifically this Order seems to be another nail in the coffin for US listed Chinese companies. Given the fact the NASDAQ price seems to dictate the HK and London prices I think Hutchmed needs to think whether a US listing is in the best interest of shareholders. This has been an absolute disaster for all those institutional shareholders, many of who took shares at $30. The company needs to ditch NASDAQ and London, get a Star market listing and maintain the HK one. The geo-politics mean this has become uninvestable. Massive financial, commercial and clinical progress has made no difference to the Company's valuation | nerdofsteel | |
18/5/2023 18:46 | And Nasdaq price down 6.55% so far today. | mcmather | |
10/5/2023 18:41 | sheer malaise, no interest, low volume, and clearly there will be no decent uplift here for years.....too many people have lost far too much money, and that includes all the institutional investors, some of whom paid $30+ per share.....ouch | nerdofsteel | |
09/5/2023 11:17 | God I hope this gets bought soon | nerdofsteel | |
08/5/2023 17:25 | Hopefully we will get bought at some point soon, the stress of continuing to lose money and holding a company whose value is governed by geo-political risk and activity in the Strait of Taiwan is far too stressful | nerdofsteel | |
02/5/2023 08:28 | No sense at all other than China is at loggerheads with the US and its allies.The geopolitical risk is outweighing Hutchmed’s medical advances.Plus,the management of the company are pretty naive when it comes to dealing with market sentiment and nurturing investors.It is disappointing that the Takeda deal hasn’t altered perception. | steeplejack | |
29/4/2023 14:12 | Despite the huge pipeline, clear runway to free cashflow in 2025/6 and massive progress (+ a few setbacks) this is valued the same it it was 8 years ago, which makes no sense at all. | nerdofsteel | |
25/4/2023 11:43 | > HUTCHMED (China) Ltd 250.00 GBX −20.00 (7.41%) | maywillow | |
25/4/2023 11:14 | Apparently Morgan Stanley reinstated HCM China "Equal-Weight" today and yet we are down nearly 7.5% on the day so far. HCM are really being a disappointment re: the share price. | lauders | |
18/4/2023 07:24 | Aye, might well zap up after this news Next Resistance seems to be 284p then a huge gap to 335p Expecting an exciting day cheers | florenceorbis | |
13/4/2023 12:24 | PENCILLED IN RESISTANCE AT 296.50p | florenceorbis | |
13/4/2023 09:53 | Having held HCM in varying quantities for a number of years,i can say that i haven't got the faintest idea of how the shares are likely to move from month to month let alone day to day.Its a mystery. | steeplejack |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions